Guardant Health, Inc.
A precision-oncology company that spots cancer with simple blood tests, including the Shield test, the first FDA-approved blood test for colorectal cancer screening, plus the Guardant360 CDx for guiding treatment and Guardant Reveal for watching for recurrence. Co-founded in 2012 by two Stanford PhDs, Helmy Eltoukhy and AmirAli Talasaz, it was built on the idea of catching cancer's genetic "signature" floating in the bloodstream. Its Shield test was designed to make cancer screening as easy as a routine blood draw, avoiding the preparation many people dread.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
Shield screening became a real second line, with volume near quadrupling . rose 44% to $335.0M and was 65.4% as screening grew 257% to $52.9M on ~66,000 tests versus ~16,000 a year ago, while widened to $120.1M. The company has $1.2B in cash and a growing screening business that has not yet closed the operating gap.
Q2 FY2026 revenue rose 44% YoY to $335M driven by 257% screening growth and 38% oncology volume growth, while net loss widened to $120M.
Interest-rate risk is limited to immaterial investment fair-value changes; foreign-currency risk is currently insignificant but expected to grow with international expansion.
The information under the caption “Commitments and Contingencies – Legal Proceedings” in Note 9 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, i…
The information under the caption “Commitments and Contingencies – Legal Proceedings” in Note 9 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.
Read original filing text →Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as risks that affect businesses in general. In addition to the information set forth…
Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 19, 2026. The risks and uncertainties disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. During the second quarter of fiscal 2026, there were no material changes to our previously disclosed risk factors. These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
Read original filing text →